GoldenGolden
Advanced Search
Genentech

Genentech

Biotechnology company that discovers, develops, manufactures and commercializes therapeutic products for serious or life-threatening medical conditions. Disease areas include oncology, immunology, ophthalmology, metabolism and virology. Genentech has been a member of the Roche Group since 2009.

In 2009 Genentech became a member of the Roche Group and the two companies combined their pharmaceutical operations in the US. The San Francisco campus of Genentech serves as headquarters for Roche pharmaceutical operations in the US. Operating as an independent center within Roche is Genentech Research and Early Development.

Genentech was founded by Robert A. Swanson (1947-1999), a venture capitalist, and biochemist Dr. Herbert W. Boyer. Boyer along with Stanley Cohen were pioneers in recombinant DNA technology.

Genetech has drug manufacturing facilities in South San Francisco, Vacaville and Oceanside, California. Genetech focused on large-scale biologics and products for about 30 years. A shift towards developing therapies that target smaller patient populations began around 2013. Genentech has two commercial large volume products, Herceptin and Rituxan, of which they produce more than 2000 kg per year. The company has six products that classify as standard volume products, between 300 kg and 2000 kg per year, as well as three in clinical trials. As of 2019 Genetech had four products considered small volume, less than 300 kg per year, and nine small volume products in the pipeline.

Genentech is developing a virtual reality simulator for eye surgery.

Products
Biooncology

Alecensa® (alectinib)

Avastin® (bevacizumab)

Cotellic® (cobimetinib)

Erivedge® (vismodegib)

Gazyva® (obinutuzumab)

Herceptin® (trastuzumab)

Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk)

Kadcyla® (ado-trastuzumab emtansine)

Perjeta® (pertuzumab)

Rituxan® (rituximab [Oncology])

Rituxan Hycela™ (rituximab and hyaluronidase human)

Tarceva® (erlotinib)

Tecentriq® (atezolizumab)

Venclexta® (venetoclax)

Xeloda® (capecitabine)

Zelboraf® (vemurafenib)

Immunology and Ophthalmology

Actemra® (tocilizumab)

Esbriet® (pirfenidone)

Lucentis™ (ranibizumab injection)

Rituxan® (rituximab [Immunology])

Xolair® (omalizumab)

Metabolism and Primary Care

Activase® (alteplase)

Cathflo Activase® (alteplase)

Nutropin AQ® (somatropin (rDNA origin) for injection)

TNKase® (tenecteplase)

Neurology

Ocrevus® (ocrelizumab)

Virology and Specialty Care

CellCept® (mycophenolate mofetil)

Pegasys® (peginterferon alfa-2a)

Pulmozyme® (dornase alfa)

Tamiflu® (oseltamivir phosphate)

Valcyte® (valganciclovir hydrochloride)

Xofluza ™ (baloxavir marboxil)

Other

Boniva Injection® (ibandronate sodium)

Boniva Tablets® (ibandronate sodium)

Cytovene® (ganciclovir)

Fuzeon® (enfuvirtide)

Hemlibra® (emicizumab-kxwh)

Invirase® (saquinavir mesylate)

Klonopin® (clonazepam)

Valium® (diazepam)

Timeline

November 23, 2020
OneOncology and Genentech announce the first clinical trial available to patients through OneR, the OneOncology Research Network.
May 18, 2020
Flatiron Health, Foundation Medicine, and Genentech partner to launch Novel Prospective Lung Cancer Clinical Study.
1976
Genentech raises a $100,000 seed round from Kleiner Perkins Caufield & Byers.

Funding rounds

Patents

Products

People

Name
Role
LinkedIn

aakanksha patel

Employee

Aaron Yip

Employee

Aashima Singhal

Founder

Abraham Gacad

Employee

Adam Tomashek

Employee

...

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Kyle LaHucik
September 27, 2021
FierceBiotech
Roche's Genentech will start communicating personalized information to patients, clinical trial participants and providers via a digital chatbot. The goal is to be able to provide information on a smartphone to more people.
Emmy Lucas
September 20, 2021
FierceBiotech
Jeffrey Stafford and his team of industry veterans have seen their biotechs go on to be acquired by the likes of Genentech, Bristol Myers Squibb and Celgene. Now, the collective is ready for its next venture: launching RNA biotech 858 Therapeutics with a $60 million series A fundraising.
Kyle LaHucik
August 26, 2021
FierceBiotech
DiCE Molecules raised $60 million in a series C extension on Tuesday. The next day, the eight-year-old preclinical biotech filed for an initial public offering to take its oral small-molecule therapeutics into the clinic.
Alex Keown
July 8, 2021
BioSpace
The two were charged with conspiracy to commit trade secret theft and wire fraud, international money laundering and obstruction of justice.
Alex Keown
June 25, 2021
BioSpace
Roche had a big week, scoring wins but also stepping away from its gene therapy partnership with 4D Molecular Therapeutics.
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.